Dong M, et al. - Researchers compared the effectiveness and toxicity of pegylated liposomal doxorubicin (PLD) and epirubicin as neoadjuvant chemotherapy for invasive breast cancer in this case-control study. According to clinical TNM staging and taxane combination, women with invasive breast cancer who received neoadjuvant chemotherapy with regimens containing PLD (PLD group) were analyzed and 1:2 matched with those who received regimens containing epirubicin (epirubicin group). The present data indicated that PLD provides potentially similar effectiveness and relatively less toxicity compared to epirubicin in neoadjuvant chemotherapy for invasive breast cancer.